Table 3.
Summary of Lipid peroxides and nitric oxide analysis in RIN5F cells treated with Alloxan (Pre-treatment) /STZ(Simultaneous) and suboptimal doses of AA (10 μg/ml) + BDNF (50 ng/ml)
| SUMMARY OF THE ANALYSIS OF LIPID PEROXIDES AND NITRIC OXIDE LEVELS IN RIN5F CELLS TREATED WITH AL/STZ | |||||
|---|---|---|---|---|---|
| CHEMICAL | GROUP | LIPID PEROXIDES (μM TMOP) | NITRIC OXIDE (μM Nitrite) | ||
| Supernatant Lysates | Supernatant Lysates | ||||
| ALLOXAN | CONTROL | 0.47 ± 0.04 | 1.2 ± 0.04 | 0.58 ± 0.03 | 1.2 ± 0.03 |
| AL(6 mM) | 0.8 ± 0.04* | 1.6 ± 0.09* | 0.87 ± 0.05 | 1.4 ± 0.05* | |
| AA(10 μg/ml) | 0.45 ± 0.06 | 1.1 ± 0.02 | 0.54 ± 0.06 | 1.15 ± 0.03 | |
| BDNF(50 ng/ml) | 0.44 ± 0.03 | 1.3 ± 0.05 | 0.43 ± 0.03 | 1.18 ± 0.07 | |
| AA + BDNF | 0.37 ± 0.03 | 1.3 ± 0.1 | 0.49 ± 0.04 | 1.16 ± 0.05 | |
| AL + AA(10 μg/ml) | 1.2 ± 0.03# | 1.3 ± 0.05# | 1.42 ± 0.03 # | 1.16 ± 0.05 # | |
| AL + BDNF | 0.9 ± 0.03§ | 0.9 ± 0.05§ | 0.94 ± 0.03§ | 1.25 ± 0.02§ | |
| AL + AA + BDNF | 0.74 ± 0.06 | 1.4 ± 0.05 | 0.89 ± 0.07 | 1.12 ± 0.05 | |
| STREPTOZOTOCIN | CONTROL | 0.68 ± 0.05 | 1.3 ± 0.04 | 0.64 ± 0.04 | 1.08 ± 0.05 |
| STZ(20 mM) | 0.89 ± 0.03 | 1.6 ± 0.09 | 0.83 ± 0.04 | 1.52 ± 0.06 | |
| AA(10 μg/ml) | 0.55 ± 0.03 | 1.2 ± 0.02 | 0.61 ± 0.05 | 1.11 ± 0.02 | |
| BDNF(50 ng/ml) | 0.54 ± 0.01 | 1.2 ± 0.03 | 0.57 ± 0.02 | 1.09 ± 0.02 | |
| AA + BDNF | 0.51 ± 0.03 | 1.2 ± 0.03 | 0.58 ± 0.01 | 1.11 ± 0.05 | |
| STZ + AA(10 μg/ml) | 0.72 ± 0.06# | 0.9 ± 0.09# | 0.79 ± 0.07# | 1.09 ± 0.04# | |
| STZ + BDNF | 0.66 ± 0.08§ | 0.8 ± 0.09§ | 0.69 ± 0.4§ | 0.9 ± 0.08§ | |
| STZ + AA + BDNF | 0.59 ± 0.03 | 1.3 ± 0.03 | 0.65 ± 0.0 | 1.15 ± 0.05 | |
Lipid peroxides formed are expressed as μmoles of TMOP formed; Nitric oxide formed is expressed as μ moles of nitrite formed. *P < 0.001 Vs Untreated control and § P ≤ 0.05, # P ≤ 0.02, * P < 0.01, ** P < 0.001 Vs AL/STZ -treated group